Lin M, Paik E, Mishra B, et al. Re-creating hereditary persistence of fetal hemoglobin (PHFH) with CRISPR/CAS9 to treat sickle cell disease (SCD) and beta-thalassemia (beta-thal). EHA 2017, abstract S147.
Positief advies vergoeding etranacogene dezaparvovec (Hemgenix) voor behandeling hemofilie B
jul 2024 | Benigne hematologie